Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2907684 | 0.89 | HSD17B14 (0.43) | CYP11B2DYRK1AHSD17B14LCKSCN9A | |
| SCHEMBL5560772 | 0.85 | CYP11B2 (0.42) | CYP11B2MMP13PIN1DYRK1ASCN9A | |
| SCHEMBL5561501 | 0.84 | PIN1 (0.49) | CYP11B2PIN1DYRK1AHSD17B14GRM2 | |
| SCHEMBL2935296 | 0.81 | GABRP (0.48) | LCK | |
| SCHEMBL2904885 | 0.79 | GAA (0.44) | LCK | |
| SCHEMBL2908784 | 0.79 | PLA2G2A (0.51) | LCK | |
| SCHEMBL2908530 | 0.79 | PLA2G2A (0.50) | CYP11B2LCK | |
| SCHEMBL2908877 | 0.79 | GAA (0.50) | LCK | |
| SCHEMBL2910558 | 0.79 | PLA2G2A (0.54) | — | |
| SCHEMBL17769119 | 0.79 | L3MBTL1 (0.57) | MMP13LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217794-B2 | Compounds and methods for treatment of thrombosis | DAIAMED, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20050143317-A1 | Compounds and methods for treatment of thrombosis | EXITHERA PHARMACEUTICALS LLC | 2005-06-30 | — | — | US | disclosed |
| WO-2004103270-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS | SUNTORY PHARMACEUTICAL RESEARCH LABORATORIES LLC (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004089297-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS | SUNTORY PHARMACEUTICAL RESEARCH LABORATORIES, LLC (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143317-A1 | Compounds and methods for treatment of thrombosis | SERPINC1, F11, F13B | CYP11B2 2296/4885MMP13 85/4885PIN1 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.